Peptide Hydrogels for Nerve-Root Repair

Evidence

Brachial plexus root avulsion tears nerve roots from the spinal cord, creating a difficult repair problem: surviving motor neurons must extend axons far enough to reconnect with muscle before denervation-related atrophy becomes entrenched. Two independent rat studies placed peptide-loaded hydrogels near the injured and replanted root. They used different materials and peptide mechanisms, but both evaluated whether local treatment was followed by motor-neuron preservation, nerve or neuromuscular rebuilding, and better forelimb movement.

The newer study, first published July 29, 2026, tested an injectable dual-network hydrogel called HGα. One physical network formed through zinc-induced self-assembly of glycyrrhizic acid. A second, covalent network combined photocrosslinked methacryloyl hyaluronic acid with a peptide designed to mimic 6′-sialyllactose. Laboratory tests reported injectability, tissue adhesion, and antioxidant capacity. These features matter because an irregular injury site creates both a delivery problem and a damaged local environment.

In a rat brachial plexus root-avulsion model, the HGα group showed improved forelimb motor function at eight weeks. Half of the treated rats reached the maximum score of 5 on the Terzis Grooming Test. The abstract also reports preservation of spinal motor neurons, modulation of local inflammation, remyelination of the musculocutaneous nerve, and reduced muscle atrophy. The ingested source does not provide the group size, numerical comparator results, variance, or component-control table, so those outcomes support a directional system-level finding rather than a precise estimate of the peptide's independent contribution.

The second study provides a more detailed comparison. Researchers used 40 adult female Sprague-Dawley rats, randomized among control, blank-hydrogel, free-NEP1-40, and NEP1-40-loaded-hydrogel groups. They avulsed the C5–C7 roots, replanted C6, and placed 100 microliters of a temperature-sensitive PLGA-PEG-PLGA hydrogel carrying NEP1-40 around the replanted root. NEP1-40 is a peptide antagonist of the Nogo-66 receptor pathway, which otherwise restricts axon growth. The free-peptide group instead received intraperitoneal NEP1-40 for 14 days.

Release testing showed that the hydrogel released about 37% of its NEP1-40 on day one and about 70% over 14 days. At six weeks, mean Terzis Grooming Test scores were 3.25 for control, 3.75 for blank hydrogel, 4.25 for free peptide, and 4.63 for peptide-loaded hydrogel. The loaded-hydrogel and free-peptide groups each scored significantly above control, although the report does not establish a statistically significant loaded-versus-free difference for that endpoint.

Tissue measurements connected movement with several points along the repair pathway. Ratios of surviving anterior-horn motor neurons on the injured versus healthy side were 51.33% in control, 57.33% with blank hydrogel, 72.33% with free NEP1-40, and 75.67% with loaded hydrogel. Fluoro-Gold tracing found more functionally connected motor neurons with loaded hydrogel than with control or free peptide. Relative to control, motor-endplate area was 27.3% higher and injured-biceps muscle-fiber diameter was 28.8% higher in the loaded-hydrogel group. These are anatomical and behavioral results in one animal model, not evidence of restored human arm function.

Analysis — Local Materials Shape Repair

The cross-study pattern is that local peptide delivery is being designed as a repair environment, not merely as a container that releases a drug. In the NEP1-40 study, the thermogel filled the irregular root-replantation site while sustaining a peptide intended to loosen an axon-growth brake. In the HGα study, adhesion and the dual network were paired with antioxidant and inflammation-related effects while the mimetic peptide was covalently integrated. The studies therefore converge on a hypothesis: keeping a peptide at the lesion may matter most when the surrounding material also addresses the physical and biochemical barriers to reconnection. This is analysis across preclinical studies, not an established treatment principle.

The older experiment also shows why component controls are decisive. Its blank-hydrogel and free-peptide arms separated some material, peptide, and combined effects, and the combined group produced the strongest reported values across several endpoints. The newer abstract reports a multifunctional composite but does not expose equivalent comparisons, so improved movement cannot be assigned specifically to the mimetic peptide, glycyrrhizic-acid network, hyaluronic-acid network, or their interaction. A stronger next experiment would compare every component and the complete material while measuring release, local peptide persistence, motor-neuron survival, axon tracing, remyelination, muscle preservation, and blinded behavior on the same timeline.

Limitations

Both studies were preclinical rat experiments conducted alongside nerve-root replantation; neither tested people, long-term durability, manufacturing consistency, or delayed treatment. Their timelines differed, with the NEP1-40 study reporting six-week outcomes and the HGα abstract emphasizing week eight. They also used different peptides, materials, and mechanistic targets, so the numerical results cannot be pooled.

Evidence depth is uneven. The NEP1-40 paper was available as commercially reusable full text, allowing review of allocation, treatment groups, release testing, and endpoint sample sizes. Even there, some tissue analyses used only three or four animals per group, and multiple endpoints increase the need for independent replication. The HGα source was abstract-only. It reports a striking maximum grooming score in 50% of treated rats but omits the denominator, comparator distribution, uncertainty, safety findings, and full component controls from the ingested record.

Neither study establishes whether measured peptides remained intact at the injury site for the required duration, whether inflammatory changes caused the functional differences, or whether benefits would persist after the materials degraded. Replication with preregistered endpoints, complete dose and release measurements, blinded analyses, longer follow-up, toxicology, and direct loaded-versus-free peptide comparisons would be needed before the apparent convergence could support a translational claim.